

Coagulation Factor XI - Pipeline Review, H2 2020

<https://marketpublishers.com/r/CABF03573CEFEN.html>

Date: October 2020

Pages: 71

Price: US\$ 3,500.00 (Single User License)

ID: CABF03573CEFEN

Abstracts

Coagulation Factor XI - Pipeline Review, H2 2020

SUMMARY

According to the recently published report 'Coagulation Factor XI - Pipeline Review, H2 2020'; Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) pipeline Target constitutes close to 22 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Factor XI or plasma thromboplastin antecedent is the zymogen form of factor X_{II}. Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. Inhibitors of factor XIa include protein Z-dependent protease inhibitor.

The report 'Coagulation Factor XI - Pipeline Review, H2 2020' outlays comprehensive information on the Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 7, 8 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Hematological Disorders, Infectious Disease and Genito Urinary System And Sex Hormones which include indications Thrombosis, Bleeding And Clotting Disorders, Venous Thromboembolism, Arterial Thrombosis, Venous (Vein) Thrombosis, Acute Ischemic Stroke, Hemophilia C (Factor XI Deficiency), Sepsis, Stroke, Atrial Fibrillation, Cerebral

Infarction (Brain Infarction), End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Hemorrhagic Fever, Ischemic Stroke and Myocardial Infarction.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)

The report reviews Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics and enlists all their major and minor projects

The report assesses Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) -
Overview

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) -
Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) -
Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) -
Companies Involved in Therapeutics Development

Anthos Therapeutics Inc

Aronora Inc

Bayer AG

Bio Products Laboratory Ltd

Bristol-Myers Squibb Co

Cambryn Biologics LLC

eXithera Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Jiangsu Hengrui Medicine Co Ltd

Mochida Pharmaceutical Co Ltd

Novartis AG

Ono Pharmaceutical Co Ltd

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) -
Drug Profiles

7300 Series - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AB-012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AB-022 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

abelacimab [INN] - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-2433334 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-262084 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-962212 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986209 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

coagulation factor XI (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

coagulation factor XI (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

coagulation factor XI (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EP-7041 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-FXILRx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-FXIRx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

milvexian - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MR-1007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-7269 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-7684 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

osocimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-2285 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Coagulation Factor XI for Bleeding and Clotting Disorders -

Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Factor XI for Bleeding And Clotting Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Factor XIa for Arterial Thrombosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) -
Dormant Products

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) -
Discontinued Products

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) -
Product Development Milestones

Featured News & Press Releases

Sep 17, 2020: eXIthera announces publication of EP-7041 data demonstrating safe antithrombotic activity in ECMO

Oct 28, 2019: Ionis Pharmaceuticals presents on its drug candidate IONIS-FXI-LRx at DIA/FDA Oligonucleotide Conference

Oct 09, 2019: Ionis' Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results

Nov 13, 2017: eXIthera Presents Clinical Data on Novel Small Molecule FXIa Inhibitor EP-7041 at American Heart Association

Jul 03, 2017: Bayer To Present Data on BAY 1213790 at ISTH 2017

Nov 01, 2016: Ionis Pharmaceuticals Reports Positive Phase 2 Data for IONIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis

Jul 04, 2016: MorphoSys Receives Clinical Milestone for Start of Phase 1 Trial in Prevention of Thrombosis with Novel Antibody

Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis

Feb 24, 2015: Bayer HealthCare and Aronora Establish Partnership for the Pre-Clinical Manufacturing of AB-022

Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery

Nov 18, 2014: Isis Pharmaceuticals To Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting

May 22, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery

May 22, 2014: Cambryn Biologics Receives From FDA Orphan Drug Designation For Human Factor XI

Apr 19, 2013: CML HealthCare's Subsidiary Hemostasis Reference Labs Receives Contract Extension From Isis Pharma

Oct 29, 2012: Isis Pharma Initiates Phase II Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indication, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Anthos Therapeutics Inc, H2 2020
Pipeline by Aronora Inc, H2 2020
Pipeline by Bayer AG, H2 2020
Pipeline by Bio Products Laboratory Ltd, H2 2020
Pipeline by Bristol-Myers Squibb Co, H2 2020
Pipeline by Cambryn Biologics LLC, H2 2020
Pipeline by eXithera Pharmaceuticals Inc, H2 2020
Pipeline by Ionis Pharmaceuticals Inc, H2 2020
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2020
Pipeline by Mochida Pharmaceutical Co Ltd, H2 2020
Pipeline by Novartis AG, H2 2020
Pipeline by Ono Pharmaceutical Co Ltd, H2 2020
Dormant Projects, H2 2020
Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Mechanism of Actions, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

I would like to order

Product name: Coagulation Factor XI - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/CABF03573CEFEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CABF03573CEFEN.html>